Pureos Bioventures β Full Portfolio
27 tracked investments Β· listed companies and verified rows first
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenNovo HoldingsSound Bioventures
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.
BiotechMedical DevicesBasel, CH
Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)inIsabella Attinger-Toller(Co-founder)in
Co-investorsredalpineSamsung VenturesVI Partnersb2ventureKinled Holding
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.
BiotechHealthtechMedical DevicesOss, NL
Renato Chirivi(Co-founder (former CSO))in
BoardPaul Peter Tak(Chair of the Board)
Co-investorsBioGeneration VenturesForbionJohnson & Johnson Innovation β JJDCSeventure PartnersBOMCurie Capital+1 more
Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications.
AI & Machine LearningBiotechDeep Tech
Rodrigo Vazquez-LombardiinSai Reddyin
Co-investorsNovo Holdings
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.
BiotechMedical DevicesZurich, CH
Co-investorsKurma PartnersYsios CapitalAdjuvant CapitalFresenius Medical Care VenturesVerve Venturesredalpine
.jpeg){kind=logo}
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedSanofi VenturesSunstone CapitalEQT Life Sciences+2 more
NovaGo Therapeutics is a biotech company developing antibody-based therapeutics to promote nerve repair and recovery following spinal cord injury.
BiotechMedical DevicesSchlieren, CH
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Co-investors+ND Capital
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Co-investorsAdvent Life SciencesBioqube VenturesBpifranceAdBio partners
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesKurma PartnersEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners+1 more
Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Peter Blume-Jensen(Executive Officer, Director)Kristina Masson(Executive Officer, Director)erick gamelininEric Devroe(Executive Officer)in
BoardMarcin Czernik(Director)Sharon Shacham(Director)
Co-investorsNew Enterprise Associates (NEA)RA Capital
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonRA CapitalBpifranceAndera PartnersAngelini VenturesKurma Partners+1 more
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo Holdings+5 more
HealthtechParis
Ronald Buggage(Executive Officer)Thierry Bordet(Executive Officer)Francine Behar Cohen(Executive Officer, Promoter)Patricia Zilliox(Executive Officer, Director, Promoter)
Co-investorsKaristaPontifax Venture Capital
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesDroia VenturesFrazier Healthcare Partners+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+5 more
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsAlexandriaBpifrance+4 more
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss.
BiotechHealthtechMedical Devices
Co-investorsPolaris Partners
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalDroia VenturesEQT Life SciencesEurazeoKurma Partners
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Ariceum TherapeuticsBaseLaunchCallio TherapeuticsCorlieve TherapeuticsEvidence BioMediarRiver RenalTridek-One
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.